2020
Radiation Therapy for Patients with Advanced Renal Cell Carcinoma
Miccio JA, Oladeru OT, Jun S, Johung KL. Radiation Therapy for Patients with Advanced Renal Cell Carcinoma. Urologic Clinics Of North America 2020, 47: 399-411. PMID: 32600541, DOI: 10.1016/j.ucl.2020.04.011.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, ImmunologicalCarcinoma, Renal CellHumansKidney NeoplasmsRadiosurgeryConceptsStereotactic body radiation therapyRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaRadiation therapyMetastatic renal cell carcinomaExcellent local controlUse of radiotherapyBody radiation therapySelect patientsSurgical candidatesMetastatic sitesSurvival outcomesPrimary tumorImmune responseStereotactic radiosurgeryLocal controlPatientsMinimal toxicityCarcinomaTherapyFuture studiesPalliationRadiotherapyRadiosurgery
2019
When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy.
Miccio J, Johung K. When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy. Oncology 2019, 33: 167-73, 177. PMID: 31095714.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyRenal cell carcinomaBody radiation therapyCell carcinomaRadiation therapyExcellent local control ratesMulti-fraction regimensExcellent local controlLocal control rateTreatment-related toxicityManagement of patientsSmall cohort sizeAdjuvant settingOligometastatic sitesNonsurgical patientsFraction radiationMetastatic sitesOnly palliationControl ratePrimary tumorTreatment approachesLocal controlCarcinomaTherapyPatients
2015
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis
Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis. Journal Of Clinical Oncology 2015, 34: 123-129. PMID: 26438117, PMCID: PMC5070549, DOI: 10.1200/jco.2015.62.0138.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnaplastic Lymphoma KinaseAntineoplastic AgentsBrain NeoplasmsCarbazolesCarcinoma, Non-Small-Cell LungCranial IrradiationCrizotinibDisease-Free SurvivalFemaleFollow-Up StudiesGene RearrangementHumansKaplan-Meier EstimateKarnofsky Performance StatusLung NeoplasmsMaleMiddle AgedMolecular Targeted TherapyNeoplasm StagingPiperidinesPrognosisProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesPyridinesPyrimidinesRadiosurgeryReceptor Protein-Tyrosine KinasesRisk AssessmentRisk FactorsSmokingSulfonesConceptsIntracranial progression-free survivalBrain metastasesProgression-free survivalPrognostic factorsLung cancerMedian intracranial progression-free survivalNon-small cell lung cancerTyrosine kinase inhibitor therapyProgressive brain metastasesRefinement of prognosisKarnofsky performance scorePercent of patientsClinical prognostic factorsPopulation of patientsSingle brain metastasisCell lung cancerKinase inhibitor therapyCox proportional hazardsMulti-institutional studyMedian OSExtracranial metastasesImproved survivalInhibitor therapyInitial treatmentMultivariable analysis